Nkowane B M, Wassilak S G, Orenstein W A, Bart K J, Schonberger L B, Hinman A R, Kew O M
JAMA. 1987 Mar 13;257(10):1335-40.
From 1973 through 1984, there were 138 cases of paralytic poliomyelitis reported in the United States; 105 (76%) were vaccine associated. Of the 105 vaccine-associated cases, 35 occurred in recipients of oral polio vaccine (OPV), 50 in contacts to OPV recipients, 14 in immune deficient individuals, and six in individuals who had no history of receiving OPV or contact with recent OPV recipients. Thirty-three (94%) of the recipient cases, 41 (82%) of the contact cases, and five (36%) of the immune deficient cases were associated with the first dose of OPV. The overall frequency of vaccine-associated poliomyelitis was one case per 2.6 million doses distributed. However, the relative frequency of paralysis associated with the first dose in the OPV series was one case per 520,000 doses vs one case per 12.3 million subsequent doses. Vaccine-associated paralytic poliomyelitis is rare and the risks of OPV are small. The greatest likelihood of paralysis occurs in association with the first dose of OPV and that likelihood is reduced in subsequent doses more for recipients than for their contacts.
1973年至1984年期间,美国共报告了138例麻痹性脊髓灰质炎病例;其中105例(76%)与疫苗相关。在这105例与疫苗相关的病例中,35例发生在口服脊髓灰质炎疫苗(OPV)接种者身上,50例发生在OPV接种者的接触者身上,14例发生在免疫缺陷个体中,6例发生在没有接种OPV史或近期未接触过OPV接种者的个体中。33例(94%)接种者病例、41例(82%)接触者病例和5例(36%)免疫缺陷病例与首剂OPV有关。疫苗相关脊髓灰质炎的总体发生率为每分发260万剂出现1例病例。然而,OPV系列中与首剂相关的麻痹相对发生率为每52万剂出现1例病例,而后续剂量为每1230万剂出现1例病例。疫苗相关麻痹性脊髓灰质炎很罕见,OPV的风险很小。麻痹最有可能发生在首剂OPV接种时,而且后续剂量中接种者发生麻痹的可能性比其接触者降低得更多。